Overview

An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.

Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of two fixed doses (16mg/day and 24mg/day) of galantamine (a drug for treating dementia) versus placebo for the treatment of patients with Alzheimer's disease, and to investigate the dose-response.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Pharmaceutical K.K.
Treatments:
Galantamine